Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
 

Learn about the flu shot, COVID-19 vaccine, and our masking policy »

Stanford Health Care

Systemic Therapy for Small-Cell Lung Cancer: ASCO-Ontario Health (Cancer Care Ontario) Guideline. Journal of clinical oncology : official journal of the American Society of Clinical Oncology Khurshid, H., Ismaila, N., Bian, J., Dabney, R., Das, M., Ellis, P., Feldman, J., Hann, C., Kulkarni, S., Laskin, J., Manochakian, R., Mishra, D. R., Preeshagul, I., Reddy, P., Saxena, A., Weinberg, F., Kalemkerian, G. P. 2023: JCO2301435

Abstract

To provide evidence-based recommendations to practicing clinicians on the management of patients with small-cell lung cancer.An Expert Panel of medical oncology, thoracic surgery, radiation oncology, pulmonary, community oncology, research methodology, and advocacy experts were convened to conduct a literature search, which included systematic reviews, meta-analyses, and randomized controlled trials published from 1990 through 2022. Outcomes of interest included response rates, overall survival, disease-free survival or recurrence-free survival, and quality of life. Expert Panel members used available evidence and informal consensus to develop evidence-based guideline recommendations.The literature search identified 95 relevant studies to inform the evidence base for this guideline.Evidence-based recommendations were developed to address systemic therapy options, timing of therapy, treatment in patients who are older or with poor performance status, role of biomarkers, and use of myeloid-supporting agents in patients with small-cell lung cancer.Additional information is available at www.asco.org/thoracic-cancer-guidelines.

View details for DOI 10.1200/JCO.23.01435

View details for PubMedID 37820295